Morgans rates IME as Add

Based upon ImexHS's 4Q cashflow report, showing a strong pick-up in cash receipts, Morgans is comfortable recommending investors buy shares (after recent weakness) prior to the FY21 result. The target price rises to $2.59 from $2.55. Add rating.

The analyst feels that extra clarity at the FY21 result, stemming from the expected splitting-out of distinct business units, will buoy sentiment toward the stock.

Sector: Health Care Equipment & Services.

Target price is $2.59.Current Price is $1.10. Difference: $1.49 - (brackets indicate current price is over target). If IME meets the Morgans target it will return approximately 58% (excluding dividends, fees and charges - negative figures indicate an expected loss).

© 2022 Acquisdata Pty Ltd., source FN Arena